25 June 2020 
EMA/CHMP/311506/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (initial authorisation) 
Veklury 
remdesivir 
On 25 June 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion, recommending the granting of a conditional2 marketing authorisation for the medicinal product 
Veklury, intended for the treatment of (SARS-CoV-2), a novel coronavirus causing a respiratory illness 
designated as coronavirus disease 2019, or COVID-19. The applicant for this medicinal product is Gilead 
Sciences Ireland UC. 
Detailed recommendations for the use of this product are described in the product information (PI), which 
is published in English here.  
The European public assessment report (EPAR) will be published after the marketing authorisation has 
been granted by the European Commission and will make this information available in all official European 
Union languages. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 A conditional marketing authorisation is granted to a medicinal product that fulfils an unmet medical need when the benefit 
to public health of immediate availability outweighs the risk inherent in the fact that additional data are still required. The 
marketing authorisation holder is likely to provide comprehensive clinical data at a later stage. 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
